Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Androgen Deprivation ◽

Blind Study ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Annals of Oncology ◽

10.1093/annonc/mdz248.008 ◽

2019 ◽

Vol 30 ◽

pp. v330-v331

Author(s):

N. Agarwal ◽

K. McQuarrie ◽

A. Bjartell ◽

S. Chowdhury ◽

A J P D S Gomes ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind ◽

MP52-20 PATIENT REPORTED OUTCOMES (PROS) IN SPARTAN, A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS PLACEBO PLUS ADT IN MEN WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

The Journal of Urology ◽

10.1016/j.juro.2018.02.1671 ◽

2018 ◽

Vol 199 (4S) ◽

Cited By ~ 1

Author(s):

Eric J. Small ◽

Fred Saad ◽

Boris A. Hadaschik ◽

Julie N. Graff ◽

Paul N. Mainwaring ◽

...

Keyword(s):

Prostate Cancer ◽

Randomized Study ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

Annals of Oncology ◽

10.1093/annonc/mdy284.054 ◽

2018 ◽

Vol 29 ◽

pp. viii295-viii296

Author(s):

S.T. Tagawa ◽

T. Dai ◽

D. Jandial

Keyword(s):

Prostate Cancer ◽

Bone Loss ◽

Androgen Deprivation ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30911-7 ◽

2018 ◽

Vol 19 (2) ◽

pp. 194-206 ◽

Cited By ~ 60

Author(s):

Kim N Chi ◽

Andrew Protheroe ◽

Alfredo Rodríguez-Antolín ◽

Gaetano Facchini ◽

Henrik Suttman ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Newly Diagnosed ◽

Phase 3 ◽

OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.81 ◽

2017 ◽

Vol 1 ◽

pp. s82

Author(s):

Steven Dayan ◽

Patricia Ogilvie ◽

Alexander Z Rivkin ◽

Steven G Yoelin ◽

Julie K Garcia ◽

...

Keyword(s):

Blind Study ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

Abstract Not Available Disclosures: Study supported by Allergan.

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30898-2 ◽

2019 ◽

Vol 20 (4) ◽

pp. 556-569 ◽

Cited By ~ 30

Author(s):

Bertrand Tombal ◽

Fred Saad ◽

David Penson ◽

Maha Hussain ◽

Cora N Sternberg ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer

JAMA ◽

10.1001/jama.2019.20675 ◽

2020 ◽

Vol 323 (2) ◽

pp. 149 ◽

Cited By ~ 23

Author(s):

Karen E. Hoffman ◽

David F. Penson ◽

Zhiguo Zhao ◽

Li-Ching Huang ◽

Ralph Conwill ◽

...

Keyword(s):

Prostate Cancer ◽

Active Surveillance ◽

Androgen Deprivation ◽

Localized Prostate Cancer ◽

External Beam Radiation ◽

External Beam ◽

Beam Radiation ◽

Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab Plus Paclitaxel vs Placebo Plus Paclitaxel Patients with Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma – Patient-Reported Outcomes and Performance Status

Annals of Oncology ◽

10.1093/annonc/mdu193.16 ◽

2014 ◽

Vol 25 ◽

pp. ii111 ◽

Cited By ~ 1

Author(s):

S.E. Al-Batran ◽

E. Van Cutsem ◽

C. Oh Sang ◽

G. Bodoky ◽

Y. Shimada ◽

...

Keyword(s):

Performance Status ◽

Gastroesophageal Junction ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

Gastroesophageal Junction Adenocarcinoma ◽

Patient Reported ◽

Previously Treated ◽

And Performance

Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.03.011 ◽

2017 ◽

Vol 15 (6) ◽

pp. 629-634.e8 ◽

Cited By ~ 2

Author(s):

Jared M. Campbell ◽

Michael E. O'Callaghan ◽

Elspeth Raymond ◽

Andrew D. Vincent ◽

Kerri R. Beckmann ◽

...

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Cancer Patients ◽

Androgen Deprivation ◽

Prognostic Accuracy ◽

Simultaneous Treatment of Moderate-to-Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines wtih OnabotulinumtoxinA from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.87 ◽

2017 ◽

Vol 1 ◽

pp. s88

Author(s):

Steven Dayan ◽

Patricia Ogilvie ◽

Alexander Z Rivkin ◽

Steven G Yoelin ◽

Julie Garcia ◽

...

Keyword(s):

Blind Study ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

Simultaneous Treatment ◽

Abstract Not AvailableStudy supported by Allergan.